Let's solve your problem together
Whole collection based on Evidence
News
WHO – Model List Of Essential Medicines
The World Health Organization (WHO) Model List of Essential Medicines (EML) is a key tool for improving global access to medicines for all conditions, including cardiovascular diseases. A review paper, published Jan. 29 in the Journal of the American College of Cardiology,discusses efforts to align the list with contemporary clinical practice guidelines.
The authors observed key factors that affect inclusion of medicines on the WHO EML: 1) cost and cost-effectiveness; 2) presence in clinical practice guidelines; 3) feedback loops; and 4) community engagement.
“WHO and national EMLs represent a collective opportunity and responsibility toward improving access to essential medicines and improving cardiovascular health,” the authors write. “We believe that the clinical cardiovascular disease community has a key role to play as petitioners, advisors, and advocates. Our work represents our collective, iterative, and expanding set of lessons learned individually – and as a group – over the past decade to modernize the WHO EML and advocate for expanded access to cardiovascular disease medications worldwide. We hope to socialize and disseminate these lessons to stimulate others to embark on similar efforts to modernize WHO EML and national EMLs.”
See more: www.onlinejacc.org/content/71/5/564?sso=1&sso_redirect_count=2&access_token=
